ADVFN - Advanced Financial Network.
HOME» NYSE » M » MDT Stock Price » MDT Stock News

Medtronic Share News

 Medtronic, Inc. Stock Price
MDT Stock Price
 Medtronic, Inc. Stock Chart
MDT Stock Chart
 Medtronic, Inc. Stock News
MDT Stock News
 Medtronic, Inc. Company Information
MDT Company Information
 Medtronic, Inc. Stock Trades
MDT Stock Trades

St Jude Medical: Early Results From Riata Lead Evaluation Consistent With Other Studies

By Melodie Warner St. Jude Medical Inc. (STJ) said early results from the Riata lead evaluation study indicate externalized conductors occur less frequently in thinner leads and the rates were consistent with other published studies. The medical-device company voluntarily stopped selling its Riata and Riata ST silicone defibrillation leads in December 2010 following reports of wires wearing through their silicone covering. The latest study's Phase 1 results found that externalized conductors--or the appearance on x-ray or fluoroscopy of conductors outside of the lead body--occurred in 9.3% of the smaller-diameter Riata ST 7F leads in the study, and in 24% of the larger-diameter Riata 8F leads. The study enrolled 724 patients at 20 sites in the U.S. and Canada. An additional 51 patients were enrolled at three sites in Japan and those results are awaiting final adjudication and will be reported at a later date. "The rates of externalized conductors in this study are consistent with other published studies involving fluoroscopic screening of patients with Riata leads," said Mark Carlson, chief medical officer and senior vice president of clinical affairs for the St. Jude Medical Cardiac Rhythm Management Division. "This study also reinforces that externalized conductors are more prevalent in larger-diameter Riata leads." The study will continue to evaluate the performance of Riata leads over the next two years to determine how they function over time. The company said in other clinical studies, the majority of leads with an externalized conductor continued to function normally. St. Jude Medical said its independent leads medical advisory board has reviewed the results and recommends no changes to existing patient management recommendations. The company said it will now focus on collecting longer-term data in the second phase of this study in order to provide physicians "timely and relevant clinical data to best support their patient management decisions." In April, St. Jude said it was seeking a retraction of a study published in the February edition of the Heart Rhythm Journal medical periodical that found heart-defibrillator wires made by the company were responsible for at least 20 deaths, citing inaccurate facts and biased analysis. The study also purported the deaths allegedly caused by Riata malfunctions were about nine times greater than a competing lead called the Quattro Secure made by Medtronic Inc. (MDT). Write to Melodie Warner at melodie.warner@dowjones.com

Stock News for Medtronic (MDT)
DateTimeHeadline
04/14/201416:42:11MARKET SNAPSHOT: Stocks Rebound; Nasdaq Erases Late Swoon
04/14/201415:49:35MARKET SNAPSHOT: Stocks Trim Gains; Nasdaq Turns Negative
04/14/201415:21:40CORRECT: Preliminary Injunction Bars Medtronic From Selling CoreValve
04/14/201411:56:03MARKET SNAPSHOT: Stocks Rebound On Retail Sales, Citi Results
04/14/201411:27:28Preliminary Injunction Bars Medtronic From Selling CoreValve
04/14/201410:47:44MARKET SNAPSHOT: Stocks Boosted By Retail Sales, Citi Results
03/29/201413:52:50Medtronic Makes Surprise Turn on Blood-Pressure Device -- Update
02/18/201412:44:34Medtronic's Profit Falls Despite Revenue Growth -- Update
02/18/201409:18:21U.S. Hot Stocks: Hot Stocks to Watch
02/17/201408:52:36MARKET SNAPSHOT: Dividend Hikes, Consumer Clues Eyed In Week...
01/17/201418:09:10Correction to Medtronic CoreValve FDA Approval Story
01/17/201416:41:27FDA Approves Medtronic's CoreValve Heart Device -- 2nd Update
01/17/201413:52:16FDA Approves Medtronic's CoreValve Heart Device
01/15/201413:10:09Jury: Medtronic Violated Patent, Owes Edwards $392.5 Million
01/15/201412:57:27Jury Rules Medtronic Violated Patent, Awards $392.5 Million
11/19/201309:07:57U.S. Hot Stocks Futures: Hot Stocks to Watch
11/19/201308:17:10Medtronic 2nd-Quarter Profit Up 40%; Defibrillator Markets Shows...
11/15/201308:55:36Highbridge Capital Management 3Q 13F: Holdings As -2-
11/15/201308:55:35Highbridge Capital Management 3Q 13F: Holdings As Of Sep 30
11/15/201307:11:09AQR Capital Management 3Q 13F: Largest Purchases

Medtronic and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad